Well, sure, there may be a more general argument for FDA bureaucracy being too convoluted (though of course there are risks with it being too lax too—no surer way to see the market flooded with snake oil). But that’s general and applies to many therapies, not just genetic ones. Same goes for research costs being the big slice of the pie.
Well, sure, there may be a more general argument for FDA bureaucracy being too convoluted (though of course there are risks with it being too lax too—no surer way to see the market flooded with snake oil). But that’s general and applies to many therapies, not just genetic ones. Same goes for research costs being the big slice of the pie.
Yes, I would agree. I don’t think this necessary needs to be that expensive, though it probably will be at the start.